# OnCo record toripalimab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/toripalimab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "toripalimab" ;
  schema:name "Toripalimab"@en ;
  schema:description "A Chinese-developed PD-1 blocker that became the first immunotherapy approved in the US for nasopharyngeal cancer."@en ;
  schema:url <https://onco.cc/drugs/toripalimab/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Toripalimab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q123397307> ;
  schema:citation <https://www.onclive.com/view/fda-approves-toripalimab-for-recurrent-or-metastatic-nasopharyngeal-carcinoma> ;
  onco:status "approved" ;
  onco:modality "Monoclonal antibody (anti-PD-1)" ;
  schema:alternateName "Loqtorzi" ;
  onco:approval "US 2023: Recurrent/metastatic nasopharyngeal carcinoma, first line with chemotherapy and later lines", "China 2018: Melanoma (first of many indications)" ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/esophageal/>, <https://onco.cc/cancers/nasopharyngeal/>, <https://onco.cc/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/>, <https://onco.cc/cancers/locoregionally-advanced-nasopharyngeal-carcinoma/>, <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/resectable-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:companies <https://onco.cc/companies/junshi/>, <https://onco.cc/companies/coherus/> ;
  onco:terms <https://onco.cc/terms/irae/> ;
  onco:trials <https://onco.cc/trials/jupiter-02/>, <https://onco.cc/trials/nct07258979/>, <https://onco.cc/trials/nct06679985/>, <https://onco.cc/trials/nct07169994/>, <https://onco.cc/trials/nct06623136/>, <https://onco.cc/trials/nct05980481/>, <https://onco.cc/trials/nct05302284/>, <https://onco.cc/trials/nct06155383/>, <https://onco.cc/trials/nct06227117/>, <https://onco.cc/trials/nct06389006/>, <https://onco.cc/trials/nct07111832/>, <https://onco.cc/trials/nct05518045/>, <https://onco.cc/trials/nct06038396/>, <https://onco.cc/trials/nct06868199/>, <https://onco.cc/trials/nct07392736/>, <https://onco.cc/trials/nct05934331/>, <https://onco.cc/trials/nct06178159/>, <https://onco.cc/trials/nct06117566/>, <https://onco.cc/trials/nct06823427/>, <https://onco.cc/trials/nct06592326/>, <https://onco.cc/trials/nct06682780/>, <https://onco.cc/trials/nct07314723/>, <https://onco.cc/trials/nct05615974/>, <https://onco.cc/trials/nct04785196/>, <https://onco.cc/trials/nct06975293/>, <https://onco.cc/trials/nct06079112/>, <https://onco.cc/trials/nct06088004/>, <https://onco.cc/trials/nct07281976/>, <https://onco.cc/trials/nct06642545/>, <https://onco.cc/trials/neotorch/> .